Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Phase 2 Completed 32 enrolled Medimetriks Pharmaceuticals, Inc

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.

Timeline

Start: 2016-10
Primary completion: 2017-06-08
Completion: 2017-06-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MM36	Unknown	1 %	Topical

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Summary

Timeline

Drugs

Indications